Nurix Therapeutics' (NRIX) Overweight Rating Reaffirmed at Stephens

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report)'s stock had its "overweight" rating reissued by equities researchers at Stephens in a report issued on Thursday,Benzinga reports. They currently have a $30.00 price objective on the stock. Stephens' target price would indicate a potential upside of 127.62% from the company's previous close.

Several other analysts have also recently commented on the stock. Needham & Company LLC restated a "buy" rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Stifel Nicolaus reduced their price target on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. HC Wainwright restated a "buy" rating and issued a $36.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. Leerink Partnrs upgraded Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Finally, Wall Street Zen raised shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, Nurix Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $30.12.

Nurix Therapeutics Trading Up 7.9%

Shares of NASDAQ:NRIX opened at $13.18 on Thursday. Nurix Therapeutics has a 12 month low of $8.18 and a 12 month high of $29.56. The company has a 50-day moving average price of $11.18 and a 200 day moving average price of $13.94. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -4.71 and a beta of 2.15.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 9th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.27. Nurix Therapeutics had a negative net margin of 369.40% and a negative return on equity of 47.49%. The company had revenue of $44,056 billion for the quarter, compared to the consensus estimate of $16.26 million. As a group, equities analysts forecast that Nurix Therapeutics will post -2.99 EPS for the current year.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 6,198 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total value of $70,223.34. Following the sale, the chief financial officer owned 33,724 shares of the company's stock, valued at $382,092.92. The trade was a 15.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gwenn Hansen sold 3,377 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider directly owned 61,516 shares of the company's stock, valued at approximately $707,434. This trade represents a 5.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,013 shares of company stock worth $137,096 over the last three months. Insiders own 7.40% of the company's stock.

Hedge Funds Weigh In On Nurix Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. boosted its stake in shares of Nurix Therapeutics by 9.5% during the first quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company's stock valued at $6,029,000 after purchasing an additional 44,002 shares during the period. Rhumbline Advisers lifted its position in Nurix Therapeutics by 7.0% during the 1st quarter. Rhumbline Advisers now owns 110,488 shares of the company's stock valued at $1,313,000 after acquiring an additional 7,255 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Nurix Therapeutics by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company's stock worth $1,895,000 after acquiring an additional 12,817 shares in the last quarter. Millennium Management LLC boosted its holdings in Nurix Therapeutics by 106.2% in the first quarter. Millennium Management LLC now owns 874,399 shares of the company's stock worth $10,388,000 after acquiring an additional 450,262 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Nurix Therapeutics by 11.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company's stock valued at $593,000 after buying an additional 5,286 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.